Silvan Tuerkcan

Work

Analyst Silvan Tuerkcan works at JMP and is focused on the Healthcare sector with 111 price targets and ratings documented since 2019 spanning on 13 stocks. Analyst's average stock valuation to be materialised ratio is 31.18% with an average time for price targets to be met of 27.42 days.

Most recent stock forecast was given on TSHA, Taysha Gene Therapies Inc. at 01-Feb-2023.

Silvan Tuerkcan best performing recommendations are on TPTX (TURNING POINT THERAPEUTICS, INC).
The best stock recommendation documented was for GBIO at 1/19/2023. The price target of $7 was fulfilled within 15 days with a profit of $2.39 (51.84%) receiving and performance score of 34.56.

Average potential price target upside

EXEL LOGC MGNX NTLA RLAY TPTX TSHA CLLS GBIO MRTX SGEN CRSP VOR

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

24

$6.45 (36.75%)

25

18 days ago

0/8 (0%)

$8.29 (44.33%)

Buy

24

$6.45 (36.75%)

28

26 days ago

0/3 (0%)

$14.26 (72.40%)

Buy

32

$14.45 (82.34%)

35

1 months 28 days ago

0/8 (0%)

$15.52 (78.71%)

Buy

21

$3.45 (19.66%)

26

3 months 4 days ago

1/4 (25%)

$5.46 (30.05%)

172

Hold

22

$4.45 (25.36%)

23

3 months 4 days ago

6/11 (54.55%)

$2.26 (11.75%)

149

Show more analysts
EXEL LOGC MGNX NTLA RLAY TPTX TSHA CLLS GBIO MRTX SGEN CRSP VOR